5463939
Last Update Posted: 2022-11-15
Recruiting status is unknown
All Genders accepted | 18 Years + |
Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.
Eligibility
Relevant conditions:
Relapsed or Refractory Multiple Myeloma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov